Overview

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Androgen Receptor Antagonists
Androgens
Immune Checkpoint Inhibitors